Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Audentes Therapeutics, Inc. (BOLD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 01/15/2020 |
4
| Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 183,384 shares
@ $60, valued at
$11M
Disposed/sold 3,829 options to buy
@ $2.7649, valued at
$10.6k
Disposed/sold 6,263 options to buy
@ $9.4988, valued at
$59.5k
Disposed/sold 73,781 options to buy
@ $15.26, valued at
$1.1M
Disposed/sold 75,000 options to buy
@ $27.39, valued at
$2.1M
Disposed/sold 65,000 options to buy
@ $24.74, valued at
$1.6M
|
|
| 01/15/2020 |
4
| Smith Julie (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Disposed/sold 18,000 options to buy
@ $17.85, valued at
$321.3k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Schuetz Thomas J. (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 89,695 shares
@ $60, valued at
$5.4M
Disposed/sold 18,086 options to buy
@ $0.7804, valued at
$14.1k
Disposed/sold 5,605 options to buy
@ $2.1852, valued at
$12.2k
Disposed/sold 9,000 options to buy
@ $15.03, valued at
$135.3k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 261,458 shares
@ $60, valued at
$15.7M
Unknown transaction of 171,814 shares
@ $60, valued at
$10.3M
Disposed/sold 143,569 options to buy
@ $9.4988, valued at
$1.4M
Disposed/sold 188,334 options to buy
@ $15.26, valued at
$2.9M
Disposed/sold 225,000 options to buy
@ $27.39, valued at
$6.2M
Disposed/sold 177,450 options to buy
@ $24.74, valued at
$4.4M
|
|
| 01/15/2020 |
4
| Mosbrooker Eric (SVP, Chief Commercial Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 26,919 shares
@ $60, valued at
$1.6M
Disposed/sold 87,750 options to buy
@ $22.01, valued at
$1.9M
|
|
| 01/15/2020 |
4
| Morrison Scott W (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Disposed/sold 33,635 options to buy
@ $9.4988, valued at
$319.5k
Disposed/sold 9,000 options to buy
@ $15.03, valued at
$135.3k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 32,705 shares
@ $60, valued at
$2M
Disposed/sold 104,000 options to buy
@ $37.26, valued at
$3.9M
|
|
| 01/15/2020 |
4
| LANGE LOUIS G (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 265,799 shares
@ $60, valued at
$15.9M
Unknown transaction of 13,678 shares
@ $60, valued at
$820.7k
Unknown transaction of 32,343 shares
@ $60, valued at
$1.9M
Unknown transaction of 3,555 shares
@ $60, valued at
$213.3k
Disposed/sold 18,000 options to buy
@ $15.03, valued at
$270.5k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Jarrett Jennifer (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Disposed/sold 18,000 options to buy
@ $14.7, valued at
$264.6k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 104,439 shares
@ $60, valued at
$6.3M
Disposed/sold 110,703 options to buy
@ $2.7649, valued at
$306.1k
Disposed/sold 548 options to buy
@ $9.4988, valued at
$5.2k
Disposed/sold 40,883 options to buy
@ $15.26, valued at
$623.9k
Disposed/sold 93,109 options to buy
@ $27.39, valued at
$2.6M
Disposed/sold 25,000 options to buy
@ $36.39, valued at
$909.8k
Disposed/sold 50,105 options to buy
@ $24.74, valued at
$1.2M
|
|
| 01/15/2020 |
4
| Goldberg Mark Alan (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 1,500 shares
@ $60, valued at
$90k
Disposed/sold 18,000 options to buy
@ $33.91, valued at
$610.4k
Disposed/sold 4,500 options to buy
@ $38, valued at
$171k
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Conner Edward R. (SVP, Chief Medical Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 24,584 shares
@ $60, valued at
$1.5M
Disposed/sold 90,000 options to buy
@ $36.08, valued at
$3.2M
|
|
| 01/10/2020 |
4
| Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Exercised 144,669 options to buy
@ $2.7649, valued at
$400k
Exercised 6,219 options to buy
@ $15.26, valued at
$94.9k
|
|
| 01/10/2020 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Gifted 12,500 shares
@ $0
Exercised 64,751 options to buy
@ $0.78, valued at
$50.5k
Exercised 74,297 options to buy
@ $2.19, valued at
$162.7k
Exercised 11,824 options to buy
@ $9.5, valued at
$112.3k
Exercised 11,666 options to buy
@ $15.26, valued at
$178k
|
|
| 12/27/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/16/2019 |
4
| Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 8,681 shares
@ $59.37, valued at
$515.4k
Paid exercise price by delivering 21,458 shares
@ $59.37, valued at
$1.3M
Exercised 41,321 options to buy
@ $2.7649, valued at
$114.2k
|
|
| 12/16/2019 |
4
| Mosbrooker Eric (SVP, Chief Commercial Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 4,881 shares
@ $59.37, valued at
$289.8k
|
|
| 12/16/2019 |
4
| Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 4,628 shares
@ $59.37, valued at
$274.8k
|
|
| 12/16/2019 |
4
| Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 8,681 shares
@ $59.37, valued at
$515.4k
Paid exercise price by delivering 88,928 shares
@ $59.37, valued at
$5.3M
Exercised 45,726 options to buy
@ $2.7649, valued at
$126.4k
Exercised 5,715 options to buy
@ $9.4988, valued at
$54.3k
Exercised 74,117 options to buy
@ $15.26, valued at
$1.1M
Exercised 6,891 options to buy
@ $27.39, valued at
$188.7k
Exercised 14,895 options to buy
@ $24.74, valued at
$368.5k
|
|
| 12/16/2019 |
4
| Conner Edward R. (SVP, Chief Medical Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 5,416 shares
@ $59.37, valued at
$321.5k
|
|
| 12/09/2019 |
4
| Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 505 shares
@ $59.21, valued at
$29.9k
|
|
| 12/09/2019 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,974 shares
@ $59.21, valued at
$116.9k
|
|
| 12/09/2019 |
4
| Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 505 shares
@ $59.21, valued at
$29.9k
|
|
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/25/2019 |
4
| LANGE LOUIS G (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 9,755 shares
@ $32.149, valued at
$313.6k
Sold 245 shares
@ $32.6628, valued at
$8k
Sold 1,000 shares
@ $32.182, valued at
$32.2k
|
|
| 09/09/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/09/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/09/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/14/2019 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 19,000 shares
@ $34.0163, valued at
$646.3k
Sold 1,000 shares
@ $34.525, valued at
$34.5k
Exercised 20,000 options to buy
@ $9.5, valued at
$190k
|
|
| 07/17/2019 |
4
| Conner Edward R. (SVP, Chief Medical Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Granted 30,000 shares
@ $0
Granted 90,000 options to buy
@ $36.08, valued at
$3.2M
|
|
| 06/26/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2019 |
4
| PRASAD SUYASH (Senior VP & Chief Med Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 757 shares
@ $37.31, valued at
$28.2k
|
|
| 06/07/2019 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 3,332 shares
@ $37.31, valued at
$124.3k
|
|
| 06/07/2019 |
4
| Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,009 shares
@ $37.31, valued at
$37.6k
|
|
|
|
|